Aidea Pharma: Sodium Dolutegravir API receives approval for listing application

Zhitong
2025.10.27 10:09

Aidea Pharma announced that its wholly-owned subsidiary, Yangzhou Aidea Pharmaceutical Technology Co., Ltd., received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration on October 27, 2025. The name of the raw material drug is Dolutegravir Sodium, and the registration number is Y20240000542. This raw material drug is part of the company's fundraising project for the R&D of high-end generic drugs for HIV, specifically the sub-project ADC201 formulation, indicated for use in combination with other antiretroviral drugs for the treatment of adult and pediatric patients aged 12 years and older infected with the human immunodeficiency virus. This approval will further ensure the supply and quality of the raw material drug, reduce production costs, and enhance the company's core competitiveness. It is expected to have no significant impact on the company's recent operations

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.